Leukemia, Myeloid, Chronic Clinical Trial
Official title:
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic myeloid leukemia who are in accelerated phase or blast phase (blast crisis) with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors
study was designed to assess the hematologic response associated with treatment of oral panobinostat. Hematologic response is defined as the overall of complete hematologic response (CHR), and of no evidence of leukemia (NEL) and of the return to chronic phase (RTC). Hematologic responses were to be confirmed after 4 weeks, and all criteria listed below for each type of response were to be concomitantly met to result into a response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
| Completed |
NCT00186342 -
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
|
N/A | |
| Completed |
NCT00759837 -
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00538109 -
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
N/A | |
| Completed |
NCT00040105 -
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
|
Phase 1 | |
| Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
| Recruiting |
NCT01015742 -
Unrelated Double Umbilical Cord Blood Units Transplantation
|
Phase 2/Phase 3 | |
| Completed |
NCT00406393 -
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
|
Phase 3 | |
| Completed |
NCT00246662 -
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00264160 -
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
|
Phase 2/Phase 3 | |
| Terminated |
NCT00306332 -
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
| Terminated |
NCT00058747 -
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
|
Phase 2 | |
| Active, not recruiting |
NCT00538447 -
Prospective Database for Chronic Myelogenous Leukemia
|
N/A | |
| Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
| Completed |
NCT00034684 -
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04260022 -
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
|
Phase 1 | |
| Terminated |
NCT00167180 -
Post Transplant Donor Lymphocyte Infusion
|
Phase 2 | |
| Completed |
NCT00455221 -
Safety Assessment of a Multipeptide-gene Vaccine in CML
|
Phase 1 | |
| Completed |
NCT00298987 -
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
|
Phase 2 | |
| Completed |
NCT00763763 -
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
|
Phase 2 |